Bamifylline

DB13203

small molecule experimental

Deskripsi

Bamifylline is a selective A1 adenosine receptor antagonist.

Struktur Molekul 2D

Berat 385.468
Wujud -

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

608 Data
Deferasirox The serum concentration of Bamifylline can be increased when it is combined with Deferasirox.
Peginterferon alfa-2b The serum concentration of Bamifylline can be increased when it is combined with Peginterferon alfa-2b.
Leflunomide The serum concentration of Bamifylline can be decreased when it is combined with Leflunomide.
Teriflunomide The serum concentration of Bamifylline can be decreased when it is combined with Teriflunomide.
Regadenoson Bamifylline may decrease effectiveness of Regadenoson as a diagnostic agent.
Adalimumab The serum concentration of Bamifylline can be decreased when it is combined with Adalimumab.
Adenosine The therapeutic efficacy of Adenosine can be decreased when used in combination with Bamifylline.
Allopurinol The serum concentration of Bamifylline can be increased when it is combined with Allopurinol.
Carbamazepine The serum concentration of Bamifylline can be decreased when it is combined with Carbamazepine.
Cimetidine The metabolism of Bamifylline can be decreased when combined with Cimetidine.
Disulfiram The serum concentration of Bamifylline can be increased when it is combined with Disulfiram.
Febuxostat The serum concentration of the active metabolites of Bamifylline can be increased when Bamifylline is used in combination with Febuxostat.
Fluvoxamine The metabolism of Bamifylline can be decreased when combined with Fluvoxamine.
Formoterol The risk or severity of hypokalemia can be increased when Bamifylline is combined with Formoterol.
Indacaterol The risk or severity of adverse effects can be increased when Bamifylline is combined with Indacaterol.
Isoniazid The serum concentration of Bamifylline can be increased when it is combined with Isoniazid.
Lithium citrate The serum concentration of Lithium citrate can be decreased when it is combined with Bamifylline.
Lithium carbonate The serum concentration of Lithium carbonate can be decreased when it is combined with Bamifylline.
Lithium hydroxide The serum concentration of Lithium hydroxide can be decreased when it is combined with Bamifylline.
Mexiletine The metabolism of Bamifylline can be decreased when combined with Mexiletine.
Olodaterol Bamifylline may increase the hyperkalemic activities of Olodaterol.
Pancuronium The therapeutic efficacy of Pancuronium can be decreased when used in combination with Bamifylline.
Pentoxifylline The serum concentration of Bamifylline can be increased when it is combined with Pentoxifylline.
Phenytoin The serum concentration of Bamifylline can be decreased when it is combined with Phenytoin.
Fosphenytoin The serum concentration of Bamifylline can be decreased when it is combined with Fosphenytoin.
Propafenone The serum concentration of Bamifylline can be increased when it is combined with Propafenone.
Quinine The serum concentration of Bamifylline can be increased when it is combined with Quinine.
Quinidine The serum concentration of Bamifylline can be increased when it is combined with Quinidine.
Riociguat Bamifylline may increase the hypotensive activities of Riociguat.
Thiabendazole The metabolism of Bamifylline can be decreased when combined with Thiabendazole.
Ticlopidine The metabolism of Bamifylline can be decreased when combined with Ticlopidine.
Zafirlukast The serum concentration of Zafirlukast can be decreased when it is combined with Bamifylline.
Probenecid The serum concentration of Bamifylline can be increased when it is combined with Probenecid.
Abiraterone The serum concentration of Bamifylline can be increased when it is combined with Abiraterone.
Isoprenaline The serum concentration of Bamifylline can be decreased when it is combined with Isoprenaline.
Cyproterone acetate The metabolism of Bamifylline can be increased when combined with Cyproterone acetate.
Amphetamine The risk or severity of adverse effects can be increased when Amphetamine is combined with Bamifylline.
Phentermine The risk or severity of adverse effects can be increased when Phentermine is combined with Bamifylline.
Midodrine The risk or severity of adverse effects can be increased when Midodrine is combined with Bamifylline.
Norepinephrine The risk or severity of adverse effects can be increased when Norepinephrine is combined with Bamifylline.
Phenylephrine The risk or severity of adverse effects can be increased when Phenylephrine is combined with Bamifylline.
Phenylpropanolamine The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Bamifylline.
Labetalol The risk or severity of adverse effects can be increased when Labetalol is combined with Bamifylline.
Metaraminol The risk or severity of adverse effects can be increased when Metaraminol is combined with Bamifylline.
Epinephrine The risk or severity of adverse effects can be increased when Epinephrine is combined with Bamifylline.
Methoxamine The risk or severity of adverse effects can be increased when Methoxamine is combined with Bamifylline.
Orciprenaline The risk or severity of adverse effects can be increased when Orciprenaline is combined with Bamifylline.
Phenmetrazine The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Bamifylline.
Dobutamine The risk or severity of adverse effects can be increased when Dobutamine is combined with Bamifylline.
Pseudoephedrine The risk or severity of adverse effects can be increased when Pseudoephedrine is combined with Bamifylline.
Benzphetamine The risk or severity of adverse effects can be increased when Benzphetamine is combined with Bamifylline.
Ritodrine The risk or severity of adverse effects can be increased when Ritodrine is combined with Bamifylline.
Terbutaline The risk or severity of adverse effects can be increased when Terbutaline is combined with Bamifylline.
Oxymetazoline The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Bamifylline.
Diethylpropion The risk or severity of adverse effects can be increased when Diethylpropion is combined with Bamifylline.
Dopamine The risk or severity of adverse effects can be increased when Dopamine is combined with Bamifylline.
Acebutolol The risk or severity of adverse effects can be increased when Acebutolol is combined with Bamifylline.
Lisdexamfetamine The risk or severity of adverse effects can be increased when Lisdexamfetamine is combined with Bamifylline.
Fenoterol The risk or severity of adverse effects can be increased when Fenoterol is combined with Bamifylline.
Ephedrine The risk or severity of adverse effects can be increased when Ephedrine is combined with Bamifylline.
Mephentermine The risk or severity of adverse effects can be increased when Mephentermine is combined with Bamifylline.
Procaterol The risk or severity of adverse effects can be increased when Procaterol is combined with Bamifylline.
Clenbuterol The risk or severity of adverse effects can be increased when Clenbuterol is combined with Bamifylline.
MMDA The risk or severity of adverse effects can be increased when MMDA is combined with Bamifylline.
Midomafetamine The risk or severity of adverse effects can be increased when Midomafetamine is combined with Bamifylline.
2,5-Dimethoxy-4-ethylamphetamine The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Bamifylline.
4-Bromo-2,5-dimethoxyamphetamine The risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Bamifylline.
Tenamfetamine The risk or severity of adverse effects can be increased when Tenamfetamine is combined with Bamifylline.
Chlorphentermine The risk or severity of adverse effects can be increased when Chlorphentermine is combined with Bamifylline.
Methylenedioxyethamphetamine The risk or severity of adverse effects can be increased when Methylenedioxyethamphetamine is combined with Bamifylline.
Dextroamphetamine The risk or severity of adverse effects can be increased when Dextroamphetamine is combined with Bamifylline.
Metamfetamine The risk or severity of adverse effects can be increased when Metamfetamine is combined with Bamifylline.
Celiprolol The risk or severity of adverse effects can be increased when Celiprolol is combined with Bamifylline.
Nylidrin The risk or severity of adverse effects can be increased when Nylidrin is combined with Bamifylline.
Tetryzoline The risk or severity of adverse effects can be increased when Tetryzoline is combined with Bamifylline.
Tyramine The risk or severity of adverse effects can be increased when Tyramine is combined with Bamifylline.
Isoxsuprine The risk or severity of adverse effects can be increased when Isoxsuprine is combined with Bamifylline.
Etilefrine The risk or severity of adverse effects can be increased when Etilefrine is combined with Bamifylline.
Synephrine The risk or severity of adverse effects can be increased when Synephrine is combined with Bamifylline.
Hydroxyamphetamine The risk or severity of adverse effects can be increased when Hydroxyamphetamine is combined with Bamifylline.
Iofetamine I-123 The risk or severity of adverse effects can be increased when Iofetamine I-123 is combined with Bamifylline.
Racepinephrine The risk or severity of adverse effects can be increased when Racepinephrine is combined with Bamifylline.
Ritobegron The risk or severity of adverse effects can be increased when Ritobegron is combined with Bamifylline.
Bucindolol The risk or severity of adverse effects can be increased when Bucindolol is combined with Bamifylline.
Tramazoline The risk or severity of adverse effects can be increased when Tramazoline is combined with Bamifylline.
Mephedrone The risk or severity of adverse effects can be increased when Mephedrone is combined with Bamifylline.
Fenozolone The risk or severity of adverse effects can be increased when Fenozolone is combined with Bamifylline.
Methoxyphenamine The risk or severity of adverse effects can be increased when Methoxyphenamine is combined with Bamifylline.
Tretoquinol The risk or severity of adverse effects can be increased when Tretoquinol is combined with Bamifylline.
Gepefrine The risk or severity of adverse effects can be increased when Gepefrine is combined with Bamifylline.
Epanolol The risk or severity of adverse effects can be increased when Epanolol is combined with Bamifylline.
Prenalterol The risk or severity of adverse effects can be increased when Prenalterol is combined with Bamifylline.
Mefenorex The risk or severity of adverse effects can be increased when Mefenorex is combined with Bamifylline.
2,5-Dimethoxy-4-ethylthioamphetamine The risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Bamifylline.
Esmolol The risk or severity of adverse effects can be increased when Esmolol is combined with Bamifylline.
Betaxolol The risk or severity of adverse effects can be increased when Betaxolol is combined with Bamifylline.
Metoprolol The risk or severity of adverse effects can be increased when Metoprolol is combined with Bamifylline.
Atenolol The risk or severity of adverse effects can be increased when Atenolol is combined with Bamifylline.
Timolol The risk or severity of adverse effects can be increased when Timolol is combined with Bamifylline.
Sotalol The risk or severity of adverse effects can be increased when Sotalol is combined with Bamifylline.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul